Ibáñez Lourdes, López-Bermejo Abel, Díaz Marta, Marcos Maria Victoria, de Zegher Francis
Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Passeig de Sant Joan de Déu 2, Esplugues, Barcelona, Spain.
J Clin Endocrinol Metab. 2008 May;93(5):1841-5. doi: 10.1210/jc.2008-0013. Epub 2008 Mar 4.
A low birth weight (LBW) tends to be followed by overweight due to an excess of fat, including visceral fat. LBW girls with precocious pubarche (PP) (pubic hair < 8 yr) are at high risk for developing an adipose state of hyperinsulinemic androgen excess that leads toward early menarche. We explored the effects of insulin sensitization with metformin in LBW-PP girls. SETTING, DESIGN, PATIENTS, INTERVENTION: Prepubertal LBW girls with PP (mean body weight 2.4 kg; age 7.9 yr; body mass index 18.4 kg/m(2)) were studied. Girls were randomly assigned to remain untreated (n=19) or receive metformin for 4 yr (n = 19; 425 mg/d for 2 yr, then 850 mg/d for 2 yr).
At the start and after 4 yr, height, weight, fasting insulin, glucose, IGF-I, testosterone, lipids, leptin, high molecular weight adiponectin, body composition by absorptiometry, abdominal fat partitioning (only 4 yr) by magnetic resonance imaging, and menarcheal status were determined.
Metformin-treated girls gained on average 5.5 kg (or approximately 50%) less fat, after 4 yr were less insulin resistant and less hyperandrogenic, had lower IGF-I levels and a less atherogenic lipid profile, and were less likely to be post-menarcheal than untreated girls, whereas their gain in height, lean mass, and bone mineral density were similar. After 4 yr, untreated girls had more visceral fat, a higher ratio of visceral-to-sc fat, and a higher leptin-to-high molecular weight adiponectin ratio (all approximately 50% higher) than metformin-treated girls.
Long-term metformin treatment appears to reduce total and visceral fat in LBW-PP girls, and to delay menarche without attenuating linear growth, thereby opening the perspective that adult height may be increased.
低出生体重(LBW)往往会因脂肪过多,包括内脏脂肪过多,而导致超重。性早熟(PP)(阴毛出现年龄<8岁)的低出生体重女孩发生高胰岛素血症性雄激素过多脂肪状态并导致初潮提前的风险很高。我们探讨了二甲双胍改善胰岛素敏感性对低出生体重-性早熟女孩的影响。
设置、设计、患者、干预措施:对青春期前患有性早熟的低出生体重女孩(平均体重2.4kg;年龄7.9岁;体重指数18.4kg/m²)进行研究。女孩们被随机分配为不接受治疗(n=19)或接受二甲双胍治疗4年(n=19;最初2年425mg/天,随后2年850mg/天)。
在开始时和4年后,测定身高、体重、空腹胰岛素、血糖、胰岛素样生长因子-I(IGF-I)、睾酮、血脂、瘦素、高分子量脂联素、通过吸收法测定的身体成分、通过磁共振成像测定的腹部脂肪分布(仅在4年后)以及月经初潮状态。
接受二甲双胍治疗的女孩平均少增加5.5kg(约50%)脂肪,4年后胰岛素抵抗减轻、雄激素过多情况改善,IGF-I水平降低且血脂谱致动脉粥样硬化性降低,与未治疗的女孩相比月经初潮的可能性更小,而她们在身高、瘦体重和骨密度方面的增加相似。4年后,未治疗的女孩比接受二甲双胍治疗的女孩有更多的内脏脂肪、更高的内脏与皮下脂肪比例以及更高的瘦素与高分子量脂联素比例(均高出约50%)。
长期二甲双胍治疗似乎可减少低出生体重-性早熟女孩的总体脂肪和内脏脂肪,并延迟月经初潮,同时不影响线性生长,从而为增加成年身高带来了希望。